212779-19-6 Usage
Uses
Used in Organic Synthesis:
2,3,5-Trichlorobenzeneboronic acid is used as a building block for the synthesis of various pharmaceuticals and agrochemicals, due to its ability to form carbon-carbon bonds through the Suzuki-Miyaura coupling reaction.
Used in the Suzuki-Miyaura Coupling Reaction:
2,3,5-Trichlorobenzeneboronic acid is used as a versatile reagent in the Suzuki-Miyaura coupling reaction, which is a widely used method for the formation of carbon-carbon bonds, facilitating the creation of diverse organic molecules.
Used as a Catalyst in Biaryl Compound Synthesis:
In the synthesis of biaryl compounds, 2,3,5-Trichlorobenzeneboronic acid is employed as a catalyst, contributing to the development of materials with applications in materials science, medicinal chemistry, and other fields.
Used in Materials Science:
2,3,5-Trichlorobenzeneboronic acid is used in materials science for the synthesis of biaryl compounds, which have various applications in the development of new materials with specific properties.
Used in Medicinal Chemistry:
2,3,5-Trichlorobenzeneboronic acid is used in medicinal chemistry for the production of pharmaceuticals, leveraging its role in the synthesis of complex organic molecules that can have therapeutic effects.
Check Digit Verification of cas no
The CAS Registry Mumber 212779-19-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,2,7,7 and 9 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 212779-19:
(8*2)+(7*1)+(6*2)+(5*7)+(4*7)+(3*9)+(2*1)+(1*9)=136
136 % 10 = 6
So 212779-19-6 is a valid CAS Registry Number.
InChI:InChI=1/C6H4BCl3O2/c8-3-1-4(7(11)12)6(10)5(9)2-3/h1-2,11-12H
212779-19-6Relevant academic research and scientific papers
Pyrazine compounds
-
, (2008/06/13)
A compound of formula (I) wherein R1is selected from the group consisting of phenyl substituted by one or more halogen atoms, naphthyl and naphthyl substituted by one or more halogen atoms; R2is selected from the group consisting of —NH2and —NHC(═O)Ra; R3is selected from the group consisting of —NRbRc, —NHC(═O)Raand hydrogen, R4is selected from the group consisting of hydrogen, -C1-4alkyl, -C1-4alkyl substituted by one or more halogen atoms, —CN, —CH2OH, —CH2ORdand —CH2S(O)xRd; wherein Rarepresents C1-4alkyl or C3-7cycloalkyl, and Rband Rc, which may be the same or different, are selected from hydrogen and C1-4alkyl, or together with the nitrogen atom to which they are attached, form a6-membered nitrogen containing heterocycle, which heterocycle can be further susbtituted with one or more C1-4alkyl; Rdis selected from C1-4alkyl or C1-4alkyl substituted by one or more halogen atoms; x is an integer zero, one or two; and pharmaceutically acceptable derivatives thereof; with the proviso that R1does not represent (a); when R2is —NH2, and both R3and R4are hydrogen.
